Gender Disparities in Quality of Life Domains Among Hispanic Individuals with Parkinson’s Disease: A Comparative Analysis
Objective: This study aims to determine gender differences in the quality of life of Parkinson's disease (PD) among Hispanic individuals. Background: PD profoundly affects various…Deep Brain Stimulation From the Perspective of Relatives and Caregivers: A Qualitative Analysis and Caregiver Burden
Objective: One of the most important conditions for success in Deep brain stimulation (DBS), which has been proven effective for more than thirty years and…Participant-reported personal utility of genetic testing for Parkinson’s disease and interest in clinical trial participation
Objective: To investigate whether participants in the PD GENEration study (NCT04994015) perceived personal benefit from receiving genetic testing for Parkinson’s disease (PD), whether being tested…ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…Sleep disorders in Parkinson’s disease
Objective: to specify the clinical features of sleep disorders in patients with PD and their impact on quality of life indicators; assessment of the relationship…Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention
Objective: The goal of this project was to amass a cohort of individuals with hyposmia to later invite them to participate in clinical trials for…Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
Objective: Characterize dopaminergic treatment-emergent adverse events (TEAEs) reported with 24h ND0612 treatment in clinical studies. Background: Dopaminergic adverse events are commonly reported across the spectrum…NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease
Objective: To determine if either once or twice-daily bright white light therapy (BWLT) improves sleep sufficiently relative to two control LT conditions to warrant proceeding…Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.
Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.